Trial Watch; May Edition 9
Where Conviction Is Building, In Real Time
The first half of May 2026 is defined by two parallel posture shifts; antibody-drug conjugates from competing big-pharma sponsors converging on identical late-line indications, and established platform modalities crossing into new tumor categories. Three signals carry the window: AbbVie and EMD Serono opened parallel Phase 3 ADC programs in refractory mCRC against the same comparator; Merck's mRNA cancer vaccine platform (INTerpath-014) crossed into resected NSCLC Phase 3; and Novartis put DLL3 onto a CAR-T backbone (DJI136) in SCLC.
Therapeutic Areas Covered
Oncology
8 trialsINTerpath-014; Intismeran Autogene + Pembrolizumab/Berahyaluronidase vs Placebo in resected high-risk Stage I NSCLC
Personalized mRNA neoantigen vaccine moves into the largest indication test yet
Timeline
Start: May 4, 2026. Primary completion: August 2034.
Mechanism
Personalized mRNA neoantigen vaccine (Intismeran autogene, the mRNA-4157 lineage co-developed by Merck and Moderna) administered with subcutaneous pembrolizumab co-formulated with berahyaluronidase alfa. Trial enrolls completely resected high-risk Stage I patients; the earliest disease setting yet tested for this modality.
Why It Matters
The mRNA-4157 / Intismeran platform has delivered the strongest melanoma adjuvant data of the last five years (KEYNOTE-942). Crossing into Phase 3 NSCLC is the platform's first attempt at a higher-incidence cancer with much larger patient populations. If the relapse-free survival readout repeats, mRNA cancer vaccines move from a melanoma-exclusive story to a foundational adjuvant modality. BioNTech (autogene cevumeran) and Genentech are watching the same readout to position their own platforms.
Reference layer
Telisotuzumab Adizutecan (ABBV-400) + Bevacizumab vs Trifluridine/Tipiracil + Bevacizumab in refractory mCRC
c-Met-directed antibody-drug conjugate against the Lonsurf + Bev standard
Timeline
Start: May 7, 2026. Primary completion: May 2029.
Mechanism
c-Met-directed antibody-drug conjugate with a topoisomerase-1 inhibitor (TOP1i) payload, given with bevacizumab against the current standard of care (Lonsurf + Bev). c-Met expression is elevated in a meaningful subset of treatment-refractory colorectal tumors.
Why It Matters
AbbVie is staking ABBV-400 as a core platform asset post-ImmunoGen. Refractory mCRC has been dominated by Lonsurf for nearly a decade. A 700-patient global Phase 3 against that comparator is an unambiguous commercial move. The competitive read is below (see PROCEADE-CRC-03); AbbVie is not alone in this exact window.
Reference layer
PROCEADE-CRC-03; Precemtabart Tocentecan ± Bevacizumab vs Trifluridine/Tipiracil + Bevacizumab
CEACAM5-directed ADC; same week, same comparator as ABBV-400
Timeline
Start: May 6, 2026. Primary completion: October 2029.
Mechanism
CEACAM5-directed ADC with TOP1i payload, evaluated with or without bevacizumab against Lonsurf + Bev. CEACAM5 is broadly expressed in colorectal adenocarcinomas and previously underdeveloped as an ADC target.
Why It Matters
Same week, same indication, same comparator as AbbVie's ABBV-400 Phase 3 above. Two big-pharma sponsors with different ADC targets but identical payload class converging on a single refractory mCRC slot. The question for the field shifts from 'is ADC the right modality' to 'which target wins'; a much faster industry verdict than the usual single-program slog.
Reference layer
Cevostamab + Pomalidomide + Dexamethasone vs Standard of Care in 2L–4L Multiple Myeloma
FcRH5/CD3 bispecific moves from late-line salvage to earlier-line combination
Timeline
Start: May 1, 2026. Primary completion: June 2029.
Mechanism
Cevostamab is an FcRH5/CD3 bispecific T-cell engager. Roche is moving the asset from late-line salvage into 2L–4L combination with pomalidomide and dexamethasone vs investigator's choice (daratumumab, elotuzumab, carfilzomib).
Why It Matters
Bispecifics in MM (teclistamab, elranatamab, talquetamab) are all positioned in heavily pre-treated patients. Roche moving cevostamab into earlier-line Phase 3 is the first credible attempt to displace daratumumab-based regimens in 2L+. The FcRH5 target also avoids the BCMA-saturation problem that limits CAR-T/BiTE sequencing.
Reference layer
Enfortumab Vedotin + Pembrolizumab in MIBC for cystectomy-ineligible patients
Nectin-4 ADC moves into curative-intent muscle-invasive bladder cancer
Timeline
Start: May 11, 2026. Primary completion: March 2030.
Mechanism
Nectin-4-directed ADC (enfortumab vedotin) combined with pembrolizumab, evaluated in muscle-invasive bladder cancer (MIBC) patients ineligible for or declining radical cystectomy; a patient population previously underserved by approved options.
Why It Matters
EV + Pembro is already first-line standard in metastatic urothelial carcinoma. Moving the regimen into the curative-intent MIBC setting (specifically the cystectomy-ineligible cohort) is Astellas/Pfizer's bid to expand the franchise into the high-value early-disease segment. If positive, it reshapes bladder-cancer treatment algorithms.
Reference layer
ANKTIVA (Nogapendekin Alfa Inbakicept) + BCG vs BCG monotherapy in papillary NMIBC
IL-15 receptor agonist moves earlier in non-muscle-invasive bladder cancer
Timeline
Start: May 15, 2026. Primary completion: May 2032.
Mechanism
ANKTIVA is an IL-15 receptor agonist (N-803) approved in BCG-unresponsive NMIBC with CIS. This Phase 3 moves the agent earlier in the disease course; BCG-naïve and BCG-exposed high-grade papillary NMIBC; directly head-to-head against BCG monotherapy.
Why It Matters
Head-to-head against the BCG standard is the canonical late-stage expansion play for an approved agent. If positive, ANKTIVA becomes a frontline NMIBC therapy rather than a salvage option, and the BCG-naïve market opens up. Important post-AACR readout for ImmunityBio.
Reference layer
BGB-43395 + Letrozole vs CDK4/6 Inhibitors + Letrozole; 1L HR+/HER2- Breast Cancer
CDK4-selective inhibitor tested head-to-head against all three approved CDK4/6 inhibitors
Timeline
Start: May 11, 2026. Primary completion: April 2029.
Mechanism
BGB-43395 is BeOne's CDK4-selective inhibitor (sparing CDK6); a third-generation refinement on the abemaciclib/palbociclib/ribociclib class designed to reduce neutropenia by avoiding CDK6 inhibition in hematopoietic cells.
Why It Matters
Direct active-comparator Phase 3 against all three approved CDK4/6 inhibitors simultaneously. This is the boldest CDK4/6 challenge since Lilly's abemaciclib first launched. Continues the broader edition-over-edition pattern of sponsors running head-to-head trials against approved class leaders rather than placebo. If BGB-43395 wins on neutropenia + non-inferior efficacy, it becomes the new standard.
Reference layer
DJI136; First DLL3-targeted CAR-T in extensive-stage SCLC
Validated DLL3 target migrates from BiTE territory onto an autologous CAR-T backbone
Timeline
Start: May 14, 2026. Primary completion: March 2031.
Mechanism
Autologous CD3+ T cells engineered to express a CAR targeting Delta-like ligand 3 (DLL3); the same target as Amgen's approved tarlatamab BiTE. Phase 1 inclusion rationale: first DLL3-targeted CAR-T cell therapy, a fundamentally new modality combination on a clinically validated target.
Why It Matters
Tarlatamab (Amgen, BiTE) proved DLL3 is druggable in SCLC. Novartis taking the same target onto a CAR-T backbone is the next escalation; autologous T-cell persistence vs continuous BiTE infusion. The strategic question: can CAR-T deliver durable responses in solid tumors where BiTEs deliver shorter-lived activity? DJI136 is the cleanest test to date. Allogene, Adicet, and several Chinese CAR-T programs are watching this readout.
Reference layer
Cardiometabolic
3 trialsPelacarsen (TQJ230) Lp(a)HORIZON Open-Label Extension
5,700 patients across 492 sites; one of the largest CV outcomes extensions in flight
Timeline
Start: May 11, 2026. Primary completion: January 2030.
Mechanism
Pelacarsen is a hepatocyte-targeted antisense oligonucleotide against apolipoprotein(a); reducing Lp(a), a genetically determined lipid particle independently associated with cardiovascular events. This is the long-term extension of the parent Lp(a)HORIZON cardiovascular outcomes trial.
Why It Matters
5,700 patients across 492 sites in one extension is one of the largest cardiovascular outcomes long-term safety programs in flight anywhere. Lp(a) is the next major lipid frontier after PCSK9; Amgen olpasiran, Silence muvalaplin, and Lilly are all building competing programs. Novartis's operational scale here signals confidence that pelacarsen will reach CV outcomes endpoints and become the foundational Lp(a) therapy.
Reference layer
AMAZE 4; NNC0487-0111 in obesity with obstructive sleep apnea on positive airway pressure
Comorbidity-specific Phase 3 running in parallel with Novo's general obesity program
Timeline
Start: May 5, 2026. Primary completion: June 2028.
Mechanism
Same Novo Nordisk next-gen obesity asset as AMAZE 12 (Edition 8); once-weekly subcutaneous injection; but this Phase 3 specifically enrolls patients with obesity plus OSA already managed on CPAP. The hypothesis: weight loss enables OSA remission and CPAP discontinuation.
Why It Matters
Novo is running a comorbidity-specific Phase 3 in parallel with its general obesity Phase 3. Strategy: build the label by indication, capture reimbursement for medical (not cosmetic) weight loss. AMAZE 4's 90-site footprint at start indicates Novo expects to enroll fast and file fast. The Eli Lilly tirzepatide SURMOUNT-OSA precedent established that OSA-specific labels are achievable; Novo is now matching that play.
Reference layer
SOLIS-1; PF-08653945 and PF-08653944, alone or in combination, in adults with overweight or obesity
Pfizer's restart at scale post-danuglipron; umbrella design across two oral assets
Timeline
Start: May 11, 2026. Primary completion: August 2027.
Mechanism
Two Pfizer next-generation oral obesity agents (PF-08653945, PF-08653944) tested as monotherapy and in combination across multiple doses against placebo. Umbrella dose-finding design pre-positions Pfizer for parallel Phase 3 launches in 2027.
Why It Matters
Pfizer's previous obesity program (danuglipron) was discontinued in 2025 over hepatotoxicity. SOLIS-1 is Pfizer's restart at scale; 872 patients, umbrella design, two parallel oral assets. This signals Pfizer has not exited the obesity market and intends to compete with Novo Nordisk (oral semaglutide), Lilly (orforglipron Phase 3 readouts), and Roche (CT-996). The oral obesity field is now a 4-sponsor race.
Reference layer
Immunology & Autoimmune
2 trialsBalinatunfib; long-term open-label extension in Crohn's disease and ulcerative colitis
Selective TNF inhibitor durability test from Sanofi's rebuilt immunology pipeline
Timeline
Start: May 12, 2026. Primary completion: May 2030.
Mechanism
Balinatunfib is a Sanofi-developed selective TNF inhibitor designed to avoid systemic TNF blockade limitations. The OLE captures long-term safety and durability in Crohn's and UC patients rolling over from the parent Phase 2 trials.
Why It Matters
Sanofi has been quietly rebuilding its immunology pipeline post-Dupixent expansion. A long-term IBD extension trial at multinational scale signals Sanofi believes balinatunfib has a real shot at differentiation in a crowded biologic landscape (anti-TNF, anti-IL-23, anti-α4β7, S1P modulators). The cumulative durability data from the OLE will determine whether Sanofi advances to Phase 3 in 2027.
Reference layer
MG-K10 humanized monoclonal antibody in moderate-to-severe atopic dermatitis
First Mabgeek asset to reach Phase 3 in a major immunology indication
Timeline
Start: May 1, 2026. Primary completion: January 2029.
Mechanism
MG-K10 is a humanized monoclonal antibody targeting an undisclosed type-2 inflammation pathway (Mabgeek has not publicly named the cytokine target). Phase 3 design includes both adult and adolescent moderate-to-severe atopic dermatitis cohorts.
Why It Matters
Chinese biotechs are entering the global atopic dermatitis biologic market once dominated by Sanofi/Regeneron's Dupixent. MG-K10 is the first Mabgeek asset to reach Phase 3 in a major immunology indication. Pricing and competitive positioning in China and ROW will be the early signal; US/EU expansion would require a separate strategy. A successful Chinese atopic AD Phase 3 reshapes regional cost benchmarks.
Reference layer
Neurology
2 trialsTenecteplase thrombolysis in the 4.5–9 hour window guided by DWI-FLAIR mismatch
MRI-guided extension of thrombolytic eligibility in acute ischemic stroke
Timeline
Start: May 1, 2026. Primary completion: December 2027.
Mechanism
Tenecteplase (TNK-tPA) administered in the extended 4.5–9 hour post-stroke window, with patient selection driven by DWI-FLAIR imaging mismatch (a marker of viable penumbra). Tests whether MRI-guided patient selection can extend thrombolytic eligibility.
Why It Matters
Tenecteplase has been steadily displacing alteplase as the preferred thrombolytic. Extending the eligibility window from the standard 4.5 hours to 9 hours; gated by imaging; could dramatically expand the addressable stroke population. WAKE-UP, EXTEND, and TIMELESS established imaging-guided thrombolysis is viable; a positive readout here moves it from selective use to standard practice in late-window stroke.
Reference layer
EMPHASIS-2; Minocycline post-IV thrombolysis in acute ischemic stroke
Largest definitive test to date of neuroprotection after thrombolysis
Timeline
Start: May 1, 2026. Primary completion: December 2028.
Mechanism
Minocycline (a tetracycline antibiotic with neuroprotective, anti-inflammatory, and matrix metalloproteinase-inhibiting effects) administered to acute ischemic stroke patients after IV thrombolysis. Hypothesis: reduce reperfusion injury and improve 90-day functional outcomes.
Why It Matters
Neuroprotection in stroke has been the graveyard of dozens of programs (NXY-059, citicoline, edaravone outside Japan). Minocycline has the most consistent preclinical signal of any repurposed agent. Tiantan's EMPHASIS-2 is the largest definitive test to date; a positive readout would change post-thrombolysis standard care globally. A negative one closes a 20-year chapter.
Reference layer
Signal Convergence
ADC competition compresses to weeks, not years
AbbVie (ABBV-400, c-Met) and EMD Serono (Precemtabart Tocentecan, CEACAM5) opened parallel Phase 3 ADC programs in refractory mCRC the same week, against the same Trifluridine/Tipiracil + Bevacizumab comparator. The decisive industry question shifts from 'is ADC the right modality' to 'which target wins'; on Year 3 timelines instead of Year 7.
Validated targets migrate across modalities
Amgen's tarlatamab (BiTE) validated DLL3 in SCLC; Novartis now puts DLL3 onto CAR-T (DJI136). Merck/Moderna's mRNA neoantigen platform delivered melanoma adjuvant data; INTerpath-014 crosses it into resected NSCLC at Phase 3. Roche's cevostamab (BiTE) moves from late-line MM into 2L–4L combination.
Lp(a) lowering reaches operational maturity
Novartis's Pelacarsen extension at 5,700 patients across 492 sites is one of the largest cardiovascular outcomes extensions in flight anywhere. Lp(a) is the post-PCSK9 lipid endgame, and Novartis is signaling confidence in foundational positioning.
Obesity goes comorbidity-specific
Novo Nordisk's AMAZE 4 (NNC0487-0111 in OSA) and Pfizer's SOLIS-1 (oral obesity umbrella) signal that the GLP-1 era has matured past 'does it work' into 'which comorbidity, which route, which positioning.'
Head-to-head against approved class leaders is now the default
BeOne running BGB-43395 against all three CDK4/6 inhibitors at once is this edition's clearest signal; a direct continuation of the Edition 8 pattern (Janssen CHARGE, Roche ZEBRHA-2, Roche BREnnA).
On Verification
Every trial in this edition is anchored to deterministic, verifiable sources sitting inline under each entry: the trial's ClinicalTrials.gov record (verified at compile time), its WHO ICTRP cross-listing (deterministic URL pattern, registry redundancy), and the sponsor's evergreen clinical trials search portal where available. Dated press-release URLs are intentionally not embedded inline because they 404 over time; the verified registry and portal links above are stable. All 15 trials in this edition have start dates verified to fall within May 1 to May 15, 2026, and none repeat from Editions 1 to 8.
About Trial Watch
Trial Watch is Kitsa's clinical intelligence layer. It captures high-signal clinical trial events and interprets where science, capital, and strategy are converging.
Keep exploring
Recommended next
- Blog
11 Early-Phase Trials and Design Frameworks to Reduce Design Risk
Discover 11 early-phase clinical trials and design frameworks redefining development strategy in 2025-2026, and what sponsors can learn to reduce late-stage failure risk.
- Blog
4 AI Misconceptions in Clinical Trials You Cannot Afford to Ignore
Four pervasive AI misconceptions in clinical trials that derail programs, inflate costs, and create regulatory exposure, with evidence on what the data actually shows.
- Blog
7 Questions to Ask Before Choosing an AI Patient Screening Solution
Before selecting an AI patient screening tool for clinical trial recruitment, ask these 7 critical questions to avoid costly mismatches and protocol failures.
- Glossary
Accelerated Approval
Accelerated Approval is an FDA pathway that allows earlier approval of drugs treating serious conditions and filling unmet medical need on the basis of a surrogate endpoint that is reasonably likely to predict clinical benefit, conditional on confirmatory post-marketing trials.